About: Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 24 October 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в листопаді 2018 (uk) article scientifique publié en 2018 (fr) artículu científicu espublizáu n'ochobre de 2018 (ast) im November 2018 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 24 October 2018 (en)
publication date	wds:Q57789804-9E3078D3-07A5-475B-AB1B-916105F3500C
publication date	2018-10-24 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57789804-552F7AC1-3C19-43C6-B0BA-E01F456B65EC
language of work or name	English
cites work	wds:Q57789804-061889D1-FCDD-4920-AA69-3F25809821B7 wds:Q57789804-09374A65-300C-4C17-9F00-0A4C8DF1B061 wds:Q57789804-0B0D88E8-5BC2-429E-8DFF-3056529CBD57 wds:Q57789804-0F31B469-65E2-4A4C-B3D2-684BA604DE97 wds:Q57789804-12CC3A15-2A95-4779-9AB2-764C12FAD20C wds:Q57789804-1CAC8DF9-ACAC-4655-AD5A-9ADB717CAC8A wds:Q57789804-1CFD0BC7-4F7A-4537-897B-6E206B067616 wds:Q57789804-27C292E9-FEA7-4A72-AEF0-5952FDBB3EB4 wds:Q57789804-28A7E2CE-EE94-476A-9F0B-DFDA896F8B3F wds:Q57789804-2A8DBEE4-7C92-482E-8757-86C529B3BDC2 wds:Q57789804-2AA1EFA6-69F4-49EC-9CA3-53DBC9DCDD00 wds:Q57789804-3366F987-26D1-42D5-8FF1-5F91BE1316F6 wds:Q57789804-3C3718B0-AD32-43A4-A83A-37CE96E2D0A7 wds:Q57789804-4AC64320-F7A5-410B-BB94-1B8F4BDA39CC wds:Q57789804-57314743-2CCC-4634-B4EB-44C94139E0CB wds:Q57789804-73F56372-20C2-47A4-B5ED-BB64F6619D57 wds:Q57789804-880C9C63-C8E2-405B-85DD-4C099DE4B6A2 wds:Q57789804-8D55A059-ABF9-4C80-9567-D7B864B47102 wds:Q57789804-8E42FEEE-A7B1-4A19-9C53-5070063FFBCD wds:Q57789804-9BDFB1B1-8998-4F8E-84A0-A053FFEA2591 wds:Q57789804-A9C8F3F9-36DC-4186-AEED-79EBF5467020 wds:Q57789804-B262965B-D951-4D5B-8452-B38D4663A0A5 wds:Q57789804-B422C951-ED27-40D8-8AB0-067A045F9F4A wds:Q57789804-B794A6BA-8508-4FB1-A299-3CC37BB6563F wds:Q57789804-B895EF0B-D67A-43A2-A7B0-434FFB992B59 wds:Q57789804-CE9F6729-ECED-4819-8034-3CE7903CA472 wds:Q57789804-D3A3FA64-CDAF-4DB7-9258-01A09E5D9C81 wds:Q57789804-DF70DD03-2717-42E2-BCBE-9A9C15164203 wds:Q57789804-E2ABEB21-1890-4284-A9AC-818DBFDF1126 wds:Q57789804-E5EFF126-2F32-4672-A122-34CB7A354AC9 wds:Q57789804-E65A3038-F3F5-49CD-B339-9A8DEF897F90 wds:Q57789804-E7F818D2-2519-43BB-B95B-061DA941E15B wds:Q57789804-E82A04DE-8F6F-484C-B776-213E45EEBB98 wds:Q57789804-F63BD39E-17B8-4B49-9F49-4BBE5BEB9AD0
cites work	Setting and revising antibacterial susceptibility breakpoints Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial Animal model pharmacokinetics and pharmacodynamics: a critical review The 2014 Garrod Lecture: EUCAST - are we heading towards international agreement? The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014). Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014 Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-dir In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014). A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016. Optimizing dosing of antibiotics in critically ill patients Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014. Combination beta-lactam and beta-lactamase-inhibitor therapy: pharmacokinetic and pharmacodynamic considerations. Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014 Avibactam Pharmacokinetic/Pharmacodynamic Targets. A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing
author name string	wds:Q57789804-4BC5F4ED-5334-40E5-8B3A-6F9566D6025F wds:Q57789804-520B102E-45B7-4F63-A9F5-66F27AF6FBD7 wds:Q57789804-5D23F376-CCEB-4C16-A650-E97DB4895AC3 wds:Q57789804-A4DCB380-98F0-4E3C-B21C-12EEF3387464 wds:Q57789804-BE201B27-2AF7-4C9E-8CC6-D28F28BED101 wds:Q57789804-E0935346-033B-427F-BC87-B7B867606286
author name string	Helen Broadhurst Gregory G Stone Angela Wardman Paul Newell Merran MacPherson Katrina Yates
rdfs:label	Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa (en) Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa (nl)
skos:prefLabel	Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa (en) Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa (nl)
name	Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa (en) Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa (nl)
author	wds:Q57789804-5C88C563-2C50-4A1E-BF26-9D650596D3E1 wds:Q57789804-71E17A5C-C6DC-4495-8CA5-AC433C8DE530 wds:Q57789804-C53FC51A-0C35-4133-96CC-D7BE5767CA4A

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software